HOME >> BIOLOGY >> NEWS
HPV testing could be future strategy for primary screening for cervical cancer

Authors of a UK study in this week's issue of THE LANCET propose a new approach for cervical cancer screening. Testing for the human papilloma virus (HPV)-the main cause of cervical cancer-could be the primary screening tool, with cytology reserved for women who test positive for HPV.

HPV testing (by genetic analysis) of cervical smears is known to be more sensitive than conventional cytology for detecting pre-malignant cervical cells called high-grade cervical intraepithelial neoplasia (CIN2/CIN3); however HPV testing is less specific than cytology (ie. it produces more 'false-positive' results). HPV testing as a primary screening approach is only feasible if appropriate management is given to women who are HPV-positive with negative or borderline cytology results.

The HART (HPV in Addition to Routine Testing) study was led by Jack Cuzick and colleagues from Cancer Research UK. Around 11,000 women aged 30-60 years from 161 GP practices in 5 UK regions participated in the study between 1998 and 2001. Women with borderline cytology and women positive for high-risk HPV with negative cytology were randomised to immediate colposcopy (detailed examination of the cervix) or to surveillance by repeat HPV testing, cytology, and colposcopy at 12 months.

HPV testing was more sensitive than borderline or worse cytology (97% compared with 77%) but slightly less specific (93% compared with 96%) for detecting malignant cells. Surveillance at 12 months was as effective as immediate colposcopy for women with minimal abnormalities, i.e., those women with either borderline cytology results (regardless of HPV status) or who were HPV positive but had negative cytology results.

Jack Cuzick comments: "HPV testing could be used for primary screening in women older than 30 years, with cytology used to triage HPV-positive women. HPV-positive women with normal or borderline cytology (about 6% of screened women) could be managed by repeat testing after 12 mon
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
4-Dec-2003


Page: 1 2

Related biology news :

1. Far more men than women favor routine paternity testing at birth
2. Nucleic acid-amplification testing further safeguards nations blood supply
3. Clinical judgement still counts strongly alongside genetic testing
4. Genetic testing of embryos to pick savior sibling OK with most Americans
5. Annual bioethics forum to explore genetic testing
6. New toxicity test could cut animal testing
7. Revised guidelines published for testing for hereditary type of colorectal cancer
8. Study calls for end to age thresholds for prenatal genetic testing
9. Genetic testing of embryos
10. High-risk women welcome genetic testing for breast cancer gene
11. Biomedical scientist testing nanoparticles as early cancer detection agent

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... ... November 13, 2019 , ... NDA Partners Chairman Carl ... affairs and program management executive with more than 33 years of regulatory and ... firm as an Expert Consultant. , Robert Peterson has extensive experience in ...
(Date:11/12/2019)... ... 12, 2019 , ... The Arnold and Mabel Beckman Foundation ... institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy and Data Science ... for the acquisition of instrumentation, development and maintenance; support for data science collaborations ...
(Date:11/7/2019)... ... , ... R3 Stem Cell is now offering its comprehensive Online Stem ... to use during checkout is FIFTYOFF and applies to both the one month access ... therapies with over 12,000 successful stem cell procedures performed nationwide. A couple years ago, ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... ... November 12, 2019 , ... ... software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies , ... Genedata Biologics® to streamline their R&D operations related to the ...
(Date:11/9/2019)... ... November 08, 2019 , ... ... pathology research, today announced the results of analyses examining the severity of ... phase 3 selonsertib studies (STELLAR). Strong correlations were demonstrated between AI-powered and ...
(Date:11/5/2019)... ... November 05, 2019 , ... Focal Healthcare ... Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By combining information ... Bx 2.0 will give urologists across Europe the ability to perform targeted transrectal ...
(Date:11/2/2019)... ... October 31, 2019 , ... drug360 graph, ... pioneer tellic. drug360 brings tellic’s expertise in biomedical language processing and machine ... quickly uncover relationships between genes, diseases, variants, phenotypes, and other biomedical entities. ...
Breaking Biology Technology:
Cached News: